Denosumab for the treatment of postmenopausal osteoporosis.
Lewiecki
E Michael
EM
New Mexico Clinical Research & Osteoporosis Center, 300 Oak St NE, Albuquerque NM 87106, lewiecki@aol.com
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects*; D002986:Clinical Trials as Topic; D000069448:Denosumab; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D010010:Osteoclasts / Q000187:drug effects; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D053245:RANK Ligand / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab